HC Wainwright reissued their buy rating on shares of Bio-Path (NASDAQ:BPTH) in a research note released on Monday, Stock Target Advisor reports. HC Wainwright currently has a $28.00 price objective on the stock.
Separately, ValuEngine lowered Bio-Path from a hold rating to a sell rating in a report on Friday, October 25th.
BPTH stock opened at $9.80 on Monday. The company has a current ratio of 13.85, a quick ratio of 13.85 and a debt-to-equity ratio of 0.02. Bio-Path has a 1 year low of $1.61 and a 1 year high of $73.52. The company has a fifty day simple moving average of $10.67 and a 200 day simple moving average of $12.58. The firm has a market cap of $30.75 million, a PE ratio of -0.68 and a beta of 3.14.
Bio-Path Company Profile
Bio-Path Holdings, Inc operates as a clinical and preclinical stage oncology focused RNAi nano particle drug development company in the United States. The company develops products based on DNAbilize, a drug delivery and antisense technology that uses P-ethoxy, which is a deoxyribonucleic acid (DNA) backbone modification intended to protect the DNA from destruction.
See Also: What is a Call Option?
Receive News & Ratings for Bio-Path Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bio-Path and related companies with MarketBeat.com's FREE daily email newsletter.